Shares of Astrana Health, Inc. (NASDAQ:ASTH – Get Free Report) have received a consensus recommendation of “Buy” from the six brokerages that are currently covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $61.20.
Several analysts have recently issued reports on ASTH shares. BTIG Research increased their price objective on Astrana Health from $60.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday, October 3rd. Robert W. Baird increased their price target on Astrana Health from $54.00 to $67.00 and gave the company an “outperform” rating in a research report on Thursday, August 15th. Truist Financial boosted their price objective on Astrana Health from $50.00 to $59.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Finally, Stifel Nicolaus raised their target price on shares of Astrana Health from $48.00 to $60.00 and gave the company a “buy” rating in a report on Thursday, August 1st.
View Our Latest Stock Report on Astrana Health
Hedge Funds Weigh In On Astrana Health
Astrana Health Stock Down 1.0 %
Shares of NASDAQ:ASTH opened at $58.33 on Thursday. The firm has a market capitalization of $3.27 billion, a PE ratio of 44.19, a price-to-earnings-growth ratio of 2.15 and a beta of 1.21. Astrana Health has a 1 year low of $28.86 and a 1 year high of $61.51. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.84 and a quick ratio of 1.84. The firm’s 50-day moving average is $51.51 and its two-hundred day moving average is $44.95.
Astrana Health (NASDAQ:ASTH – Get Free Report) last announced its earnings results on Wednesday, August 7th. The company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.01. The firm had revenue of $486.30 million for the quarter, compared to the consensus estimate of $440.68 million. Astrana Health had a net margin of 4.30% and a return on equity of 10.71%. The firm’s revenue for the quarter was up 39.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.28 EPS. Analysts predict that Astrana Health will post 1.33 EPS for the current year.
About Astrana Health
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.
Featured Articles
- Five stocks we like better than Astrana Health
- Most active stocks: Dollar volume vs share volume
- 3 Momentum Trades for October With Ample Upside Ahead
- 3 Small Caps With Big Return Potential
- Roblox Dips on Short Report—Here’s Why It Could Bounce Back Fast
- Insider Buying Explained: What Investors Need to Know
- 2 Reasons to Jump on Apple Stock Now and 1 Reason to Think Twice
Receive News & Ratings for Astrana Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrana Health and related companies with MarketBeat.com's FREE daily email newsletter.